{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-007347","form_type":"8-K","ticker":null,"cik":"0001695357","company_name":"Provention Bio, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.178369+00:00","generated_at":"2026-06-18T04:34:53.001577+00:00","sec_items":["1.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Sanofi to acquire Provention Bio for $25.00 per share, equity value ~$2.9B","bullets":["Sanofi to acquire Provention via tender offer at $25.00/share cash; equity value ~$2.9 billion.","TZIELD (teplizumab) is lead asset, first therapy to delay onset of Stage 3 type 1 diabetes.","Offer subject to majority tender, HSR clearance, and other customary conditions; no financing condition.","Provention must pay $100M termination fee; Sanofi must pay $158M reverse termination fee if antitrust fails.","Executive employment agreements amended to adjust severance multiples and provide tax gross-up (up to $15M aggregate)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-007347","json":"https://secwatch.observer/filing/0001493152-23-007347.json","markdown":"https://secwatch.observer/filing/0001493152-23-007347.md","text":"https://secwatch.observer/filing/0001493152-23-007347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223007347/0001493152-23-007347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223007347/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:34:53.001577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e4ea172c9f2b37bea38c2777dbadb4ed55195f5b","claim":"Provention Bio, Inc.: Amended and Restated Bylaws to update procedural requirements for director nominations in light of universal proxy rules and other administrative changes (effective 2023-03-09).","evidence_excerpt":"On March 9, 2023, the Company Board approved the Company's Amended and Restated Bylaws (as so amended and restated, the \"Amended Bylaws\"), effective as of such date.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223007347/0001493152-23-007347-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-09"}],"fact_type":"governance_change"},{"claim_id":"c2791b7a5e9523c7dae782eea05d25dc765a7460","claim":"Provention Bio, Inc. entered into Agreement and Plan of Merger with Sanofi S.A. (effective 2023-03-12).","evidence_excerpt":"On March 12, 2023, Provention Bio, Inc., a Delaware corporation (the \"Company\" or \"Provention\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Sanofi S.A., a French société anonyme (\"Parent\"), and Parent's indirect wholly-owned subsidiary, Zest Acquisition Sub, Inc., a Delaware corporation (\"Purchaser\").","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1695357/000149315223007347/0001493152-23-007347-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Sanofi S.A."},{"label":"Effective","value":"2023-03-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}